NewsBenzingaEli Lilly Announces Foundayo Met Primary Endpoint At Week 52 In ATTAIN-OSA Trial To Reduce Apnea-Hypopnea Index; Lowers Sleep Apnea-Specific Hypoxic Burden By Up To An Average Of 55.9% Eli Lilly Announces Foundayo Met Primary Endpoint At Week 52 In ATTAIN-OSA Trial To Reduce Apnea-Hypopnea Index; Lowers Sleep Apnea-Specific Hypoxic Burden By Up To An Average Of 55.9% Benzinga 2026.11.09 14:33 (GMT+0) Open on Benzinga Other news A whale accumulates 238,400 LINK from Binance in two days, worth about $2.2 million Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds